Premaitha Health PLC to attend key conferences in Middle East
February 06 2018 - 4:28AM
ADVFN NewsWire
Premaitha Health
plc
("Premaitha" or the
"Company")
Premaitha raises awareness
of the IONA® test
at
key conferences in the Middle East
Manchester, UK -- 6 February 2018 -- ADVFN NewsWire
-- Premaitha Health plc (AIM: NIPT), a
leading international molecular diagnostics group focused on
prenatal testing, announces it will be
participating in key conferences in the Middle East to further
raise the profile of the IONA®
test across this region.
Medlab Dubai
Medlab is one of the largest
medical laboratory exhibitions in the world and is held in Dubai
from 5 to 8 February 2018. Premaitha is hosting an exhibition stand
at the event and showcasing the IONA® test to the Medlab attendees,
comprising both existing and prospective customers and distributors
across the Middle East.
For further details, please visit: www.medlabme.com/en/home.html
Egyptian Fetal Medicine Foundation,
4th Annual Conference
The
Egyptian Fetal Medicine Foundation conference ("EFMF") will be held in Cairo, Egypt on 8 and 9 February
2018. The event attracts leading clinicians from across Egypt and
the Middle East.
Premaitha will host an exhibition stand at the
event and the Company's Head of Operations, Dr Sean Sales, will be
giving a presentation to delegates providing a clinical and
technical overview of non-invasive prenatal screening
("NIPT").
Through its participation at the event,
Premaitha aims to raise awareness of the IONA® test and engage and educate leading
fetal medicine clinicians on the benefits of adopting
NIPT.
For further details, please visit: efmf-eg.org/index.php
Premaitha's IONA® test estimates the risk of a
fetus being affected with Down's syndrome or other genetic
conditions. The test is performed on a maternal blood sample,
containing traces of fetal DNA, which is then analysed using next
generation DNA sequencing technology. The test is highly accurate
and significantly reduces the number of women who are unnecessarily
subjected to risky, invasive follow up procedures to diagnose
Down's syndrome and other genetic conditions.
Dr Stephen Little, CEO of Premaitha Health,
commented: "We continue to see increasing
traction across the Middle East for the IONA® test. These key industry events will
enable us to further raise awareness of both the
IONA® test and the
benefits of adopting NIPT, with a view to further enhancing our
distribution networks in the region."
For more information, please
contact:
|
|
Premaitha Health PLC
Dr Stephen Little, Chief Executive
Officer
Barry Hextall, Chief Financial
Officer
Joanne Cross, Head of Marketing
investors@premaitha.com
|
Tel: +44 (0)161 667 1053
|
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / James Caithie
|
Tel: +44 (0)20 7213 0880
|
finnCap (Broker)
Adrian Hargrave / Scott Mathieson (Corporate
Finance)
Andrew Burdis / Abigail Wayne (Corporate
Broking)
|
Tel: +44 (0)20 7220 0500
|
Vigo Communications
Ben Simons / Fiona Henson / Antonia
Pollock
premaitha@vigocomms.com
|
Tel: +44 (0)20 7830 9700
|
About Premaitha
Premaitha is an international molecular
diagnostics group which uses the latest advances in DNA analysis
technology to develop safer, faster and regulatory approved genetic
screening tests. The Group's primary focus is on
non-invasive
prenatal tests (NIPT) for pregnant women - an emerging,
multi-billion
dollar global market.
Premaitha's IONA® test was launched in 2015 as
the first CE-IVD NIPT test in Europe. It enables laboratories and
healthcare practitioners to offer a complete CE-marked NIPT system
in-house. The IONA® test
is performed on a maternal blood sample -
which contains traces of fetal DNA - and estimates
the risk of a fetus being affected with Down's syndrome or other genetic
conditions.
Unlike existing prenatal screening methods, due
to its high level of accuracy, the IONA® test can significantly
reduce the number of women subjected to unnecessary
invasive follow up diagnostic procedures, such as
amniocentesis, which are costly, resource intensive and carry a
risk of miscarriage.
In March 2017, Premaitha acquired Yourgene
Bioscience, a specialist next generation sequencing and
bioinformatics company based in Taiwan, with its own NIPT screening
test that operates on the same Thermo Fisher next-generation
sequencing platform as Premaitha's IONA® test. Yourgene brings
significant benefits to the Group through expanded market access in
Asia - the world's fastest growing NIPT market - as well as
opportunities for cross-selling and the ability to jointly develop
expanded test content both within NIPT and beyond.
Premaitha is headquartered in Manchester,
England, with Yourgene offices in Taipei and Singapore. Its shares
trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further
information, please visit www.premaitha.com.
Follow us on twitter
@PremaithaHealth.
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2023 to May 2024